This inventor holds 7 USPTO granted patents. Top assignees: Harvard College, Dana-Farber-Cancer Institute Inc.. Active years: 2007-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Waltham, MA (US) (2007 - 2010)
- College Station, TX (US) (2010 - 2013)
Company Filing History:
Years Active: 2007-2013
Title: Innovations and Contributions of Inventor Han Chen
Introduction
Han Chen is a notable inventor based in College Station, TX (US). He has made significant contributions to the field of biomedical research, particularly in the development of novel therapeutic compounds. With a total of 7 patents to his name, Chen's work has the potential to impact various medical conditions.
Latest Patents
Among his latest patents, Han Chen has developed compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and its derivatives. These innovations are aimed at treating cellular proliferative disorders, non-proliferative degenerative disorders, viral infections, and disorders associated with viral infections. His work on 3-3-di-substituted-oxindoles as inhibitors of translation initiation showcases his commitment to advancing medical science.
Career Highlights
Throughout his career, Han Chen has worked with prestigious institutions such as Harvard College and Dana-Farber Cancer Institute. His research has been instrumental in exploring new avenues for treatment and understanding complex biological processes.
Collaborations
Han Chen has collaborated with esteemed colleagues, including José A Halperin and Amarnath Natarajan. These partnerships have further enriched his research and contributed to the advancement of innovative solutions in the medical field.
Conclusion
Han Chen's contributions to the field of biomedical research through his patents and collaborations highlight his role as a leading inventor. His work continues to pave the way for new therapeutic approaches that could benefit many patients in need.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

